Atara Biotherapeutics stock rose 7% after its partner sought an FDA meeting to address the rejection of tabelecleucel. The FDA rejected the drug earlier this year due to trial design and analysis issues. Partner Pierre Fabre submitted a briefing to resolve these concerns regarding treatment for Epstein-Barr virus-positive PTLD.